Gleevec and Zosyn drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gleevec and Zosyn. Common interactions include pyrexia among females and atrial fibrillation among males.

The phase IV clinical study analyzes what interactions people who take Gleevec and Zosyn have. It is created by eHealthMe based on reports of 14 people who take Gleevec and Zosyn from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jan, 29, 2023

14 people who take Gleevec and Zosyn together, and have interactions are studied.

What is Gleevec?

Gleevec has active ingredients of imatinib mesylate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 34,268 Gleevec users for its effectiveness, alternative drugs and more.

What is Zosyn?

Zosyn has active ingredients of piperacillin sodium; tazobactam sodium. It is often used in pneumonia. eHealthMe is studying from 9,644 Zosyn users for its effectiveness, alternative drugs and more.

Number of Gleevec and Zosyn reports submitted per year:

Common Gleevec and Zosyn drug interactions by gender *:

female:

Pyrexia
Renal impairment
Restless legs syndrome
Sialoadenitis
Sleep apnoea syndrome
Tremor
Visual impairment
Aspergillosis
Blood sodium decreased
Bronchopulmonary aspergillosis

male:

Atrial fibrillation
Pleural effusion
Hepatic ischaemia
Ischaemic hepatitis
Paracentesis
Peptic ulcer
Pericardial effusion
Pericarditis
Pleurisy
Shock

Common Gleevec and Zosyn drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Blood sodium decreased
Inappropriate adh secretion
Tumour lysis syndrome

40-49:

n/a

50-59:

n/a

60+:

Atrial fibrillation
Pleural effusion
Hepatic ischaemia
Ischaemic hepatitis
Paracentesis
Peptic ulcer
Pericardial effusion
Pericarditis
Pleurisy
Shock

Common conditions people have *:

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 7 people, 50.00%
Primary Myelofibrosis (primary disorder of the bone marrow): 2 people, 14.29%
Thrombophlebitis Migrans (development of recurrent (i.e. migratory) superficial thrombophlebitis): 1 person, 7.14%
Sialoadenitis (inflammation of a salivary gland): 1 person, 7.14%
Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs): 1 person, 7.14%
Pain: 1 person, 7.14%
Neoplasm Recurrence (reoccurrence of tumour): 1 person, 7.14%
Metastasis (spreadable cancer to other organ from origin): 1 person, 7.14%
Gastrointestinal Stromal Tumor: 1 person, 7.14%
Cellulitis (infection under the skin): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Gleevec and Zosyn?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

O'rafferty C, McElligott F, Storey L, O'marcaigh A, Smith O, "Pneumatosis intestinalis and imatinib mesylate", Annals of hematology, 2014 Oct .

Related studies